ArticleThe Journal of infection2020
Beneficial impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study.
Fabrizio Cantini et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
108 papers cite itlatest 60 shown
this paperpooled ittrialcites it